Palonosetron Seacross Pharmaceuticals (Palonosetron)

Palonosetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting related to specific therapeutic pathways.

• Chemotherapy‑induced nausea and vomiting (CINV): Provides effective prophylaxis for acute and delayed phases in adult patients receiving moderately to highly emetogenic chemotherapy.
• Post‑operative nausea and vomiting (PONV): Reduces the incidence of nausea and vomiting after surgical procedures requiring general anesthesia.
• Radiotherapy‑induced nausea and vomiting: Helps mitigate the nausea associated with radiation treatment of the abdomen or pelvis.
• Antiemetic prophylaxis in patients receiving highly intense multimodal anti‑emetic regimens.
• Adjunctive therapy for breakthrough nausea in patients already on a standard anti‑emetic protocol.
• Support for patients under palliative care with refractory nausea that is not controlled by first‑line agents.

• Palonosetron binds with high affinity to serotonin type 3 (5‑HT3) receptors located on vagal afferent nerves in the gastrointestinal tract and the central nervous system. This binding blocks serotonin‑mediated signaling that triggers the vomiting reflex, providing a prolonged anti‑emetic effect that lasts up to 72 hours after a single dose.

Palonosetron is generally well‑tolerated, but adverse reactions can occur.

Common Side Effects

• Headache 
• Constipation 
• Fatigue 
• Dizziness 
• Injection site erythema 
• Diarrhoea 

Serious or Rare Side Effects

• QT‑interval prolongation 
• Severe hypersensitivity reactions (anaphylaxis, angio‑angelf )
• Serotonin syndrome 
• Cardiac arrhythmia 
• Pulmonary edema 
• Neuro‑muscular weakness 

• Palonosetron should be administered ​​​   
• -     
• t  ?  
• t  ....  ",